Senzime Financial Statements From 2010 to 2025
| SNZZF Stock | USD 0.54 0.09 20.00% |
Check Senzime AB financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senzime AB's main balance sheet or income statement drivers, such as , as well as many indicators such as . Senzime financial statements analysis is a perfect complement when working with Senzime AB Valuation or Volatility modules.
Senzime |
Senzime AB OTC Stock Return On Equity Analysis
Senzime AB's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Senzime AB Return On Equity | -0.64 |
Most of Senzime AB's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Senzime AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Senzime AB has a Return On Equity of -0.6434. This is 97.32% lower than that of the Healthcare sector and 92.63% lower than that of the Medical Devices industry. The return on equity for all United States stocks is 107.55% higher than that of the company.
Senzime AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Senzime AB's current stock value. Our valuation model uses many indicators to compare Senzime AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Senzime AB competition to find correlations between indicators driving Senzime AB's intrinsic value. More Info.Senzime AB is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Senzime AB's earnings, one of the primary drivers of an investment's value.About Senzime AB Financial Statements
Senzime AB stakeholders use historical fundamental indicators, such as Senzime AB's revenue or net income, to determine how well the company is positioned to perform in the future. Although Senzime AB investors may analyze each financial statement separately, they are all interrelated. For example, changes in Senzime AB's assets and liabilities are reflected in the revenues and expenses on Senzime AB's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Senzime AB. Please read more on our technical analysis and fundamental analysis pages.
Senzime AB , a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company was incorporated in 1999 and is based in Uppsala, Sweden. Senzime Ab is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Senzime OTC Stock
Senzime AB financial ratios help investors to determine whether Senzime OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Senzime with respect to the benefits of owning Senzime AB security.